Aimee Maree Wilkin, MD, MPH
- Professor, Infectious Diseases
Aimee Maree Wilkin, MD, MPH
Research Interests
- HIV Infections
- Anti-HIV Agents
- HIV-1
- Access to Care in HIV
- Health Disparities in HIV
- Education
- MD, University of Texas Medical Branch at Galveston, 1994
- Residency
- Internal Medicine, University Hospital (Cincinnati), 1997
- Fellowship
- Infectious Diseases, University Hospital (Cincinnati), 1999
- Board Certifications
- American Board of Internal Medicine, Infectious Disease
- American Board of Internal Medicine, Internal Medicine
- Positions
- Professor, Infectious Diseases
- Departments and Affiliations
- Infectious Diseases
- Office of Global Health
Research
- A Qualitative Systematic Review of Cigarette Smoking Cessation Interventions for Persons Living with HIV. Mann-Jackson L, Choi D, Sutfin EL, Song EY, Foley KL, Wilkin AM, Morse CG, Rojas NF, Oh TS, Rhodes SD. J Cancer Educ. 2019 Dec; 34(6):1045-1058.
- Physical Functioning Among Patients Aging With Human Immunodeficiency Virus (HIV) Versus HIV Uninfected: Feasibility of Using the Short Physical Performance Battery in Clinical Care of People Living With HIV Aged 50 or Older. Crane HM, Miller ME, Pierce J, Willig AL, Case ML, Wilkin AM, Brown S, Asirot MG, Fredericksen RJ, Saag MS, Landay AL, High KP. . 2019 Mar; 6(3):ofz038.
- Characteristics of Out-of-Care Patients Who Required a Referral for Re-engagement Services by Public Health Bridge Counselors Following a Brief Clinic-Based Retention Intervention. Fadul N, Willis SJ, Donovan J, Wilkin A, Durr Heine A, LeViere A, Dortche C, Quinlivan EB. AIDS Behav. 2019 Jan; 23(Suppl 1):52-60.
- Results of a Social Network Testing Intervention for HIV in Infectious Disease Clinics. LeViere A, Donovan J, Wilkin A, Keller J, Parnell H, Sampson L, Gay CL, Quinlivan EB. AIDS Behav. 2019 Jan; 23(Suppl 1):48-51.
- Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Eron JJ, Lelievre JD, Kalayjian R, Slim J, Wurapa AK, Stephens JL, McDonald C, Cua E, Wilkin A, Schmied B, McKellar M, Cox S, Majeed SR, Jiang S, Cheng A, Das M, SenGupta D. Lancet HIV. 2018 Dec;